References

  1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999; 353:1167–73
  2. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162:1245–8.
  3. Wong P, Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism. Phlebology. 2012;27 Suppl 2:2–11.
  4. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000 83:657–60.
  5. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992 232:155–60.
  6. Silverstein MD, Heit JA, Mohr DN, Petterson TM, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158:585–93.
  7. Heit JA, Silverstein MD, Mohr DN, Petterson TM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001 86:452–63.
  8. Geerts WH, Bergqvist D, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):381S-453S
  9. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004;164:17-26.
  10. Kahn SR. The Post-Thrombotic Syndrome. Hematology Am Soc Hematol Educ Program. 2010; 2010:216-20. doi: 10.1182/asheducation-2010.1.216.
  11. van Dongen CJ, Prandoni P, Frulla M, Marchiori A, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost. 2005;3:939-42.
  12. Prandoni P. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol. 2012;88:185-94.
  13. Goldhaber SZ and Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835–46
  14. National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Costing report. 2012
  15. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353:1386 –1389.
  16. Piazza G and Goldhaber S. Management of Submassive Pulmonary Embolism. Circulation. 2010;122:1124–1129.
  17. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011; 364:351–60.
  18. Isbister JP. The normal haemostatic system. Crit Care Resusc. 2008; 10:261-3
  19. Gomez K, Tuddenham EDG, McVey JH. Normal haemostasis. In Postgraduate Haematology, Sixth Edition Edited by A V. Hoffbrand, D. Catovsky, E. G. D. Tuddenham, A. R. Green © 2011 Blackwell Publishing Ltd. Chapter 29: 746–71
  20. Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005; 26:3-4
  21. Patel K. Deep Venous Thrombosis. MEDSCAPE 2014
  22. Kahn S. The post thrombotic syndrome. Thromb Res 2011; 127 Suppl. 3:S89–S92
  23. Toshner M, Pepke-Zaba J. Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. F1000Prime Rep. 2014; 6:38. doi: 10.12703/P6-38. eCollection 2014.
  24. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008 451:914–8.
  25. Weitz JI1, Gross PL. New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program. 2012;2012:536-40. doi: 10.1182/asheducation-2012.1.536.
  26. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk. 2018. NICE clinical guideline 89. Available at www.nice.org.uk/guidance/ng89
  27. Risk assessment for venous thromboembolism (VTE) – NICE https://www.nice.org.uk/guidance/ng89/resources/department-of-health-vte-risk-assessment-tool-pdf-4787149213
  28. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and HSE Clinical Care Programme in Obstetrics and Gynaecology and Irish Haematology Society - Clinical Practice Guideline Venous Thromboprophylaxis in Pregnancy. Available at: https://www.hse.ie/eng/services/publications/
  29. National Institute for Health and Clinical Excellence. Venous thromboembolism prevention quality standard. 2010 NICE quality standard 3. Available at https://www.nice.org.uk/guidance/qs3
  30. Samama M, Cohen AT, Darmon JY, et al. Comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341:793-800.
  31. Leizorovicz A, Cohen AT, Turpie AGG, et al. Randomized, placebo controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110:874–9.
  32. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. Br Med J 2006; 332:325–9.
  33. Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA. 2014; 311:717–28.
  34. National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. 2012. NICE clinical guideline 144. Available at https://www.nice.org.uk/guidance/ng158
  35. Enden T, Haig Y, Kløw NE, et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis vs standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012; 379:31-38
  36. Othieno R, Abu Affan M, Okpo E. Home vs in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2007;3(3):CD003076.
  37. Squizzato A, Donadini MP, Galli L, Dentali F, Aujesky D, Ageno W. Prognostic clinical prediction rules to identify a low-risk pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost. 2012; 10:1276–90.
  38. Carter NJ, McCormack PL, Plosker GL. Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs 2008; 68:691–710.
  39. Clexane Summary of Product Characteristics
  40. Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins. P&T 2010; 35: 95–105.
  41. Linhardt RJ, Gunay NS. Semin Thromb Hemost 1999; 25(suppl 3):5–16.
  42. Mitton BA. Antithrombin deficiency. MEDSCAPE 2014.
  43. Barras M. Anti-Xa assays. Aust Prescr 2013; 36:98–101.
  44. Xarelto® Summary of Product Characteristics
  45. Eliquis® Summary of Product Characteristics
  46. Pradaxa® Summary of Product Characteristics
  47. NHS Deep vein thrombosis https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt
  48. Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Available at https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf

 

To the top